Table 1.
Patient demographics and characteristics
| Study | No. of patients | Age (y) | No. male | Persistent AF | LVEF (%) | CHA2DS2VASc score | AAD | Repeat AF ablation |
|---|---|---|---|---|---|---|---|---|
| Pulsed field ablation | ||||||||
| Reddy (2018)20 | 22 | 65 ± 5 | 12 (55) | — | 63 ± 3 | — | — | 0 (0) |
| Reddy (2019)21 | 81 | 58 ± 11 | 60 (74) | — | 63 ± 4 | — | 69 (85) | 0 (0) |
| Loh (2020)22 | 10 | 59 ± 11 | 7 (70) | 3 (30) | — | — | 9 (90) | 0 (0) |
| Reddy (June 2020)27 | 76 | 59 ± 10 | 50 (66) | 21 (28) | 58 ± 6 | — | 72 (95) | 0 (0) |
| Reddy (September 2020)26 | 25 | 67 | 20 (80) | 25 (100) | 60 | — | 24 (96) | 0 (0) |
| Cochet (2021)24 | 18 | 58 ± 9 | 15 (83) | — | 62 ± 6 | — | 14 (78) | 0 (0) |
| Nakatani (2021)25 | 18 | 56 ± 9 | 15 (83) | — | 62 ± 6 | 0.5 (0-1) | 13 (72) | 0 (0) |
| Reddy (2021)28 | 121 | 57 ± 10 | 89 (74) | — | 63 ± 6 | — | 118 (98) | 0 (0) |
| Blockhaus (2022)23 | 23 | 57 ± 10 | 15 (65) | 11 (48) | 56 ± 8 | 1.5 ± 1.1 | — | NR |
| Ekanem (2022)29 | 1758 | 62 | 1157 (66) | 619 (35) | 55 | 2.1 | — | 114 (6.5) |
| Futing (2022)30 | 30 | 63 ± 10 | 14 (47) | 0 (0) | 60 ± 6 | — | — | 0 (0) |
| Gunawardene (2022)31 | 20 | 70 ± 10 | 12 (60) | 13 (65) | — | 2.5 (2-4) | — | NR |
| Kawamura (2022)32 | 20 | 56 ± 12 | 15 (75) | — | 64 ± 4 | — | 19 (95) | 0 (0) |
| Lemoine (2022)33 | 138 | 57 ± 12 | 91 (66) | 86 (62) | 52 ± 10 | 2.7 ± 1.7 | 26 (19) | 0 (0) |
| Schmidt (2022)34 | 191 | 69 ± 12 | 111 (58) | 72 (38) | 60 ± 10 | — | — | 0 (0.0) |
| Verma (2022)35 | 38 | 62 ± 11 | 20 (53) | 3 (8) | 60 ± 5 | 1.9 ± 1.6 | — | 0 (0.0) |
| Verma (2023)36 | 300 | 65 ± 9 | 209 (70) | 150 (50) | — | — | 187 (62) | 0 (0.0) |
| Thermal ablation | ||||||||
| RAAFT-1 (2005)13 | 70 | 54 ± 8 | — | 3 (4) | 54 ± 6 | — | 0 (0) | 0 (0.0) |
| MANTRA (2012)14 | 294 | 55 ± 10 | 206 (70) | 0 (0) | — | 0 (0-1) | 0 (0) | 0 (0.0) |
| RAAFT-2 (2014)15 | 127 | 55 ± 10 | 96 (76) | 3 (2) | 61 ± 6 | 0 (0-1) | 0 (0) | 0 (0.0) |
| FIRE AND ICE (2016)16 | 750 | 60 ± 10 | 457 (61) | 0 (0) | — | 1.9 ± 1.4 | 461 (61) | 0 (0.0) |
| CABANA (2019)17 | 2204 | 68 (62-72) | 1385 (63) | 1258 (57) | — | 3 (2-4) | — | 0 (0.0) |
| STOP AF (2020)18 | 203 | 61 ± 11 | 120 (59) | 0 (0) | 61 ± 6 | 2 (1-3) | 0 (0) | 0 (0.0) |
| EARLY-AF (2021)19 | 303 | 59 ± 11 | 214 (71) | 16 (5) | 60 ± 7 | 1.9 ± 1.1 | 0 (0) | 0 (0.0) |
Values are given as mean ± SD or n (%).
AAD = antiarrhythmic drug; AF = atrial fibrillation; CHA2DS2VASc = risk score for thromboembolic events; LVEF = left ventricular ejection fraction.